Elvitegravir is an experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. integrase inhibitor currently in phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trials.
Like raltegravir (the only drug in this class approved for use in Australia) elvitegravir will be of most use to people with multiple drug reisistance.
Integrase inhibitors target an enzyme called integrase which HIV uses to integrate its genetic code into human cells. Because this is a different point of action to that targeted by other drug classes, there is a good chance that people who have failed several prior treatment regimens will benefit from this drug, especially if it is combined with an optimised background regimen.
According to the results of phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. clinical trials, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate..
| Generic name: |
elvitegravir (EVG) |
|---|
| Pronunciation: | el-vy-TEG-ra-veer |
|---|
| Also known as: | GS-9137, JTK-303 |
|---|
| Drug class: | integrase inhibitor |
|---|
| Availability in Australia: | - Not available on the Pharmaceutical Benefits Scheme (PBS).
- This drug may be available through clinical trials in Australia.
- You may be able to import this drug from overseas for your personal use.
|
|---|
| Links: | |
|---|
Like all anti-HIV drugs, elvitegravir must be taken in combination with other drugs to be completely effective.
Your doctor will advise you on the right combination of drugs to suit your circumstances.
Dosage
150mg once daily combined with 100mg ritonavir.
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
Side effects
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
Interactions with other drugs
Studies on potential interactions between elvitegravir and other drugs have not yet been reported, but are planned and ongoing.
The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia. read more »
A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years. read more »
The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART studyA clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trialA clinical trial is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase I tests a new drug or treatment in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people; and Phase IV takes place after the drug or treatment has been licensed and marketed. is a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. Clinical trials are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase IA clinical trial designed to establish whether an experimental drug is safe for humans to take. Phase I studies determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and look for early evidence of effectiveness; these studies may include either people with HIV, HIV-negative volunteers, or both tests a new drug or treatment in a small group; Phase IIA smaller clinical trial designed to establish whether a drug is effective. Phase II studies are conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. If there is evidence that the drug is effective, a Phase III study is undertaken, with a larger number of participaants, to confirm this. expands the study to a larger group of people; Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. expands the study to an even larger group of people; and Phase IVPost-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use. takes place after the drug or treatment has been licensed and marketed. , but as usual, this important conference produced a great deal more than a single story. read more »
The table below shows all the clinical trials in the database with the keyword elvitegravir (GS-9137).
Sorry, no clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. trials database entries were found that matched your request.
This site complies with the HONcode standard for trustworthy health information: verify here. 
